IgA肾病患者血浆中miR-191-5p表达及其与肾间质纤维化相关性的研究

doi:10.3969/j.issn.1006-6233.2023.02.010

摘要
图/表
参考文献
相关文章 (6)

全文: PDF (1220 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨IgA肾病患者血浆中miR-191-5p表达及其与肾间质纤维化(RIF)相关性的研究。方法: 选择2017年2月至2022年2月我院收治的80例IgA肾病患者(IgA肾病组),根据CKD分期分为Ⅰ~Ⅱ期组(42例)、Ⅲ期组(38例),根据牛津分型分为T₀组(20例)、T₁组(39例)、T₂组(21例),另选择77例健康志愿者为对照组。实时荧光定量聚合酶链反应(qRT-PCR)检测受试者血浆miR-191-5p表达,全自动生化分析仪检测肾功能[血肌酐(Scr)、尿素氮(BUN)],酶联免疫吸附试验检测RIF指标[转化生长因子TGF-β1、TGF-α]。Pearson分析miR-191-5p表达与肾功能及RIF指标、RIF面积的相关性。结果: IgA肾病组血浆miR-191-5p表达低于对照组(P<0.05),Scr、BUN、TGF-β1、TGF-α水平高于对照组(P<0.05)。Ⅲ期组血浆miR-191-5p表达低于Ⅰ~Ⅱ期组(P<0.05),Scr、BUN、TGF-β1、TGF-α水平高于Ⅰ~Ⅱ期组(P<0.05),RIF面积大于Ⅰ~Ⅱ期组(P<0.05);T₂组血浆miR-191-5p表达低于T₀组和T₁组(P<0.05),Scr、BUN、TGF-β1、TGF-α水平高于T₀组和T₁组(P<0.05),RIF面积大于T₀组和T₁组(P<0.05)。CKD患者血浆miR-191-5p表达与RIF面积、Scr、BUN、TGF-β1、TGF-α均呈负相关(r=-0.509、-0.379、-0.311、-0.475、-0.486,P<0.05)。结论: IgA肾病患者血浆miR-191-5p表达降低,且与RIF以及肾功能下降有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： IgA肾病, 肾间质纤维化, 微小核糖核酸, miR-191-5p

Abstract：Objective: To investigate the expression of miR-191-5p in the plasma of patients with IgA nephropathy and its correlation with renal interstitial fibrosis (RIF). Methods: 80 patients with IgA nephropathy (IgA nephropathy group) admitted to our hospital from February 2017 to February 2022 were divided into stage Ⅰ~Ⅱ group (42 cases), stage Ⅲ group (38 cases) according to CKD stages. Patients were divided into the T₀ group (n = 20), T₁ group (n = 39), and T₂ group (n = 21) according to Oxford parting, and 77 healthy volunteers were selected as the control group. Plasma miR-191-5p expression was detected by Quantitative real-time polymerase chain reaction (qRT-PCR), renal function [creatinine (Scr), urea nitrogen (BUN)] were detected by the automatic biochemical analyzer, and RIF indexes [transforming growth factor TGF -β1 and TGF-α]were detected by enzyme-linked immunosorbent assay. Pearson analysis was conducted to understand the correlation between miR-191-5p expression and renal function and RIF index and RIF area. Results: The levels of serum miR-191-5P in the IgA nephropathy group were lower than those in the control group (P<0.05), and the levels of Scr, BUN, TGF -β1, and TGF-α were higher than those in the control group (P<0.05). The expression of miR-191-5p in the stage Ⅲ group was lower than that in the stageⅠ~Ⅱ group (P<0.05), Scr, BUN, TGF-β1, and the area of RIF was higher than that in stageⅠ~Ⅱ group (P<0.05). The expression of miR-191-5p in the T₂ group was lower than that in the T₁ group and T₀ group (P<0.05), Scr, BUN, TGF-β1, and the area of RIF was higher than that in the T₁ group and T₀ group (P<0.05). Plasma miR-191-5p expression was negatively correlated with RIF area, Scr, BUN, TGF-β1, and TGF-α in patients with IgA nephropathy (r=-0.509, -0.379, -0.311, -0.475, -0.486,P<0.05). Conclusion: The expression of miR-191-5p in plasma is decreased in patients with IgA nephropathy and is related to RIF and renal function decline.

Key words： IgA nephropathy Renal interstitial fibrosis Micro ribonucleic acid MiR-191-5p

基金资助:2021年河北省医学科学研究重点课题计划,(编号:20210528)

通讯作者: 刘翠红

引用本文:

夏薇青, 宋菊香, 杨二梅, 曹义甫, 王天智, 刘翠红. IgA肾病患者血浆中miR-191-5p表达及其与肾间质纤维化相关性的研究[J]. 河北医学, 2023, 29(2): 232-236.
XIA Weiqing, SONG Juxiang, YANG Ermei, et al. Study on the Expression of Mir-191-5p in Plasma and Its Correlation with Renal Interstitial Fibrosis in Patients with IgA Nephropathy. HeBei Med, 2023, 29(2): 232-236.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.02.010 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I2/232

[1] Selvaskandan H,Cheung CK,Muto M,et al.New strategies and perspectives on managing IgA nephropathy[J].Clin Exp Nephrol,2019,23(5):577-588.
[2] Martinez-Arias L,Panizo S,Alonso-Montes C,et al.Effects of calcitriol and paricalcitol on renal fibrosis in CKD[J].Nephrol Dial Transplant,2021,36(5):793-803.
[3] Zhang Y,Zhang GX,Che LS,et al.miR-212 promotes renal interstitial fibrosis by inhibiting hypoxia-inducible factor 1-α inhibitor[J].Mol Med Rep,2021,23(3):189.
[4] Calle P,Hotter G.Macrophage phenotype and fibrosis in diabetic nephropathy[J].Int Mol Sci,2020,21(8):2806.
[5] Stevens PE,Levin A.Kidney disease:improving global outcomes chronic kidney disease guideline development work group members.Evaluation and management of chronic kidney disease:synopsis of the kidney disease:improving global outcomes 2012 clinical practice guideline[J].Ann Intern Med,2013,158(11):825-830.
[6] Working Group of the International IgA Nephropathy Network and the Renal Pathology Society,Cattran DC,Coppo R,et al.The oxford classification of IgA nephropathy:rationale,clinicopathological correlations,and classification[J].Kidney Int,2009,76(5):534-545.
[7] Lichotai S,Studzińska D,Plutecka H,et al.MiR-191 as a key molecule in aneurysmal aortic remodeling[J].Biomolecules,2021,11(11):1611.
[8] Lykken EA,Li QJ.The microRNA miR-191 supports T cell survival following common γ chain signaling[J].Biol Chem,2016,291(45):23532-23544.
[9] Blume J,Zietara N,Witzlau K,et al.miR-191 modulates B-cell development and targets transcription factors E2A,Foxp1,and Egr1[J].Eur Immunol,2019,49(1):121-132.
[10] Chen P,Pan X,Zhao L,et al.MicroRNA-191-5p exerts a tumor suppressive role in renal cell carcinoma[J].Exp Ther Med,2018,15(2):1686-1693.
[11] Wu XQ,Tian XY,Wang ZW,et al.miR-191 secreted by platelet-derived microvesicles induced apoptosis of renal tubular epithelial cells and participated in renal ischemia-reperfusion injury via inhibiting CBS[J].Cell Cycle,2019,18(2):119-129.
[12] Berillo O,Huo KG,Fraulob-Aquino JC,et al.Circulating let-7g-5p and miR-191-5p are independent predictors of chronic kidney disease in hypertensive patients[J].Am Hypertens,2020,33(6):505-513.
[13] Chen J,Sun J,Hu Y,et al.MicroRNA-191-5p ameliorates amyloid-β1-40 -mediated retinal pigment epithelium cell injury by suppressing the NLRP3 inflammasome pathway[J].Faseb,2021,35(4):e21184.